Inhibition of cardiac two-pore-domain K+ (K2P) channels by the antiarrhythmic drug vernakalant--comparison with flecainide.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  European Journal of Pharmacology

• Publication date

  2014-02-05

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.ejphar.2013.12.030PMID 24374008
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cardiac expression and atrial fibrillation-associated remodeling of K₂p2.1 (TREK-1) K⁺ channels in a porcine model.

  2014cited by this paper
• The new antiarrhythmic drug vernakalant: ex vivo study of human atrial tissue from sinus rhythm and chronic atrial fibrillation.

  2013cited by this paper
• Functional characterization of zebrafish K2P18.1 (TRESK) two-pore-domain K+ channels

  2013cited by this paper
• Class I antiarrhythmic drugs inhibit human cardiac two-pore-domain K(+) (K2 ₂p) channels.

  2013cited by this paper
• Atrial selectivity of antiarrhythmic drugs

  2013cited by this paper
• Rate-Dependent Effects of Vernakalant in the Isolated Non-Remodeled Canine Left Atria Are Primarily Due to Block of the Sodium Channel: Comparison With Ranolazine and dl-Sotalol

  2012cited by this paper
• TASK1 (K2P3.1) K+ channel inhibition by endothelin‐1 is mediated through Rho kinase‐dependent phosphorylation

  2012cited by this paper
• In vivo Electrophysiological Characterization of TASK-1 Deficient Mice

  2012cited by this paper
• TREK-1 K(+) channels in the cardiovascular system: their significance and potential as a therapeutic target.

  2012cited by this paper
• PKC‐dependent activation of human K2P18.1 K+ channels

  2012cited by this paper
• Identification and functional characterization of zebrafish K(2P)10.1 (TREK2) two-pore-domain K(+) channels.

  2012cited by this paper
• Novel electrophysiological properties of dronedarone: inhibition of human cardiac two-pore-domain potassium (K2P) channels

  2012cited by this paper
• Comparison of electrophysiological and antiarrhythmic effects of vernakalant, ranolazine, and sotalol in canine pulmonary vein sleeve preparations.

  2012cited by this paper
• Carvedilol targets human K2P3.1 (TASK1) K+ leak channels

  2011cited by this paper
• hERG K+ channel-associated cardiac effects of the antidepressant drug desipramine

  2011cited by this paper
• A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation.

  2011cited by this paper
• Alternative splicing determines mRNA translation initiation and function of human K2P10.1 K+ channels

  2011cited by this paper
• Pharmacological Inhibition of the hERG Potassium Channel Is Modulated by Extracellular But Not Intracellular Acidosis

  2011cited by this paper
• Knock-Out of the Potassium Channel TASK-1 Leads to a Prolonged QT Interval and a Disturbed QRS Complex

  2011cited by this paper
• Multiple mechanisms of hERG liability: K+ current inhibition, disruption of protein trafficking, and apoptosis induced by amoxapine

  2010cited by this paper
• Molecular Background of Leak K (cid:1) Currents: Two-Pore Domain Potassium Channels

  2010cited by this paper
• A multicenter, open-label study of vernakalant for the conversion of atrial fibrillation to sinus rhythm.

  2010cited by this paper
• Novel pharmacological approaches for antiarrhythmic therapy

  2010cited by this paper
• The human cardiac K2P3.1 (TASK-1) potassium leak channel is a molecular target for the class III antiarrhythmic drug amiodarone

  2010cited by this paper
• Assessing use-dependent inhibition of the cardiac Na(+/-) current (I(Na)) in the PatchXpress automated patch clamp.

  2010cited by this paper
• Usefulness of vernakalant hydrochloride injection for rapid conversion of atrial fibrillation.

  2010cited by this paper
• New antiarrhythmic drugs for treatment of atrial fibrillation.

  2010cited by this paper
• Vernakalant

  2010cited by this paper
• Molecular background of leak K+ currents: two-pore domain potassium channels.

  2010cited by this paper
• Vernakalant Hydrochloride for the Rapid Conversion of Atrial Fibrillation After Cardiac Surgery: A Randomized, Double-Blind, Placebo-Controlled Trial

  2009cited by this paper
• Vernakalant Hydrochloride for Rapid Conversion of Atrial Fibrillation: A Phase 3, Randomized, Placebo-Controlled Trial

  2008cited by this paper
• Alternative translation initiation in rat brain yields K2P2.1 potassium channels permeable to sodium.

  2008cited by this paper
• Atrial-selective approaches for the treatment of atrial fibrillation.

  2008cited by this paper
• Regulation of two‐pore‐domain (K2P) potassium leak channels by the tyrosine kinase inhibitor genistein

  2008cited by this paper
• The Effect of Vernakalant (RSD1235), an Investigational Antiarrhythmic Agent, on Atrial Electrophysiology in Humans

  2007cited by this paper
• Vernakalant (RSD1235): a novel, atrial-selective antifibrillatory agent

  2007cited by this paper
• RSD1235 blocks late INa and suppresses early afterdepolarizations and torsades de pointes induced by class III agents.

  2006cited by this paper
• The Mechanism of Atrial Antiarrhythmic Action of RSD1235

  2005cited by this paper
• A randomized, controlled trial of RSD1235, a novel anti-arrhythmic agent, in the treatment of recent onset atrial fibrillation.

  2004cited by this paper
• Direct block of hERG potassium channels by the protein kinase C inhibitor bisindolylmaleimide I (GF109203X).

  2004cited by this paper
• Inhibition of human ether-a-go-go-related gene potassium channels by alpha 1-adrenoceptor antagonists prazosin, doxazosin, and terazosin.

  2004cited by this paper
• Inhibition of human ether-a-go-go-related gene potassium channels by α1-adrenoceptor antagonists prazosin, doxazosin, and terazosin

  2004cited by this paper
• Inhibition of cloned HERG potassium channels by the antiestrogen tamoxifen

  2003cited by this paper
• Cardiac channelopathies

  2002cited by this paper
• Potassium leak channels and the KCNK family of two-p-domain subunits

  2001cited by this paper
• Effects of flecainide, quinidine, and 4-aminopyridine on transient outward and ultrarapid delayed rectifier currents in human atrial myocytes.

  1995cited by this paper
• K+ channel blocking actions of flecainide compared with those of propafenone and quinidine in adult rat ventricular myocytes.

  1994cited by this paper

• Thyrotropin Directly Affects Cardiac Electrophysiology and Is Associated With AF Prevalence.

  2025cites this paper
• Rational design, synthesis, and evaluation of novel polypharmacological compounds targeting NaV1.5, KV1.5, and K2P channels for atrial fibrillation

  2025influential citation
• Research progress of two-pore potassium channel in myocardial ischemia-reperfusion injury

  2024cites this paper
• A reduction in atrial and pulmonary vein stretch as a therapeutic target for prevention of atrial fibrillation.

  2022cites this paper
• Pathophysiological Role of K2P Channels in Human Diseases.

  2021cites this paper
• Two-Pore-Domain Potassium (K2P-) Channels: Cardiac Expression Patterns and Disease-Specific Remodelling Processes

  2021cites this paper
• Bepridil, a class IV antiarrhythmic agent, can block the TREK-1 potassium channel

  2021cites this paper
• Contribution of K2P Potassium Channels to Cardiac Physiology and Pathophysiology

  2021cites this paper
• Mechanosensitive TREK-1 two-pore-domain potassium (K2P) channels in the cardiovascular system.

  2020cites this paper
• Cardiac K2P13.1 (THIK-1) two-pore-domain K+ channels: Pharmacological regulation and remodeling in atrial fibrillation.

  2019cites this paper
• Dynamics of propagation patterns and anti-arrhythmic mechanisms during atrial fibrillation

  2019cites this paper
• Computational Modeling of Electrophysiology and Pharmacotherapy of Atrial Fibrillation: Recent Advances and Future Challenges

  2018influential citation
• Loss of KCNK3 is a hallmark of RV hypertrophy/dysfunction associated with pulmonary hypertension

  2018cites this paper
• Loss of KCNK 3 is a hallmark of RV hypertrophy / dysfunction associated with pulmonary hypertension

  2018cites this paper
• Identification and functional characterization of zebrafish K2P17.1 (TASK‐4, TALK‐2) two‐pore‐domain K+ channels

  2018cites this paper
• Cardiovascular pharmacology of K2P17.1 (TASK-4, TALK-2) two-pore-domain K+ channels

  2018cites this paper
• Stretch-activated two-pore-domain (K2P) potassium channels in the heart: Focus on atrial fibrillation and heart failure.

  2017cites this paper
• Novel ion channel targets in atrial fibrillation

  2016cites this paper
• Atrial-Selective Potassium Channel Blockers.

  2016cites this paper
• Antiarrhythmic effect of vernakalant in electrically remodeled goat atria is caused by slowing of conduction and prolongation of postrepolarization refractoriness.

  2016cites this paper
• Therapeutic targeting of two-pore-domain potassium (K(2P)) channels in the cardiovascular system.

  2016cites this paper
• Upregulation of K2P3.1 K+ Current Causes Action Potential Shortening in Patients With Chronic Atrial Fibrillation

  2015cites this paper
• Structural and functional studies of K2P channels

  2015cites this paper
• Vernakalant activates human cardiac K(2P)17.1 background K(+) channels.

  2014cites this paper
• Cloning, functional characterization, and remodeling of K2P3.1 (TASK-1) potassium channels in a porcine model of atrial fibrillation and heart failure.

  2014cites this paper
• Inhibition of cardiac two-pore-domain K+ (K2P) channels--an emerging antiarrhythmic concept.

  2014cites this paper